Direkt zum Inhalt
Merck

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Science translational medicine (2013-01-25)
Raheleh Hatami, Anieta M Sieuwerts, Sudeh Izadmehr, Zhong Yao, Rui Fang Qiao, Luena Papa, Maxime P Look, Marcel Smid, Jessica Ohlssen, Alice C Levine, Doris Germain, David Burstein, Alexander Kirschenbaum, Analisa DiFeo, John A Foekens, Goutham Narla
ZUSAMMENFASSUNG

Metastasis is the major cause of cancer mortality. A more thorough understanding of the mechanisms driving this complex multistep process will aid in the identification and characterization of therapeutically targetable genetic drivers of disease progression. We demonstrate that KLF6-SV1, an oncogenic splice variant of the KLF6 tumor suppressor gene, is associated with increased metastatic potential and poor survival in a cohort of 671 lymph node-negative breast cancer patients. KLF6-SV1 overexpression in mammary epithelial cell lines resulted in an epithelial-to-mesenchymal-like transition and drove aggressive multiorgan metastatic disease in multiple in vivo models. Additionally, KLF6-SV1 loss-of-function studies demonstrated reversion to an epithelial and less invasive phenotype. Combined, these findings implicate KLF6-SV1 as a key driver of breast cancer metastasis that distinguishes between indolent and lethal early-stage disease and provides a potential therapeutic target for invasive breast cancer.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-Kaninchen-IgG-Antikörper der Ziege, (H+L) FITC-Konjugat, 1.0 mg/mL, Chemicon®